A single dose of Teva's experimental antibody significantly reduced gluten-induced intestinal damage and inflammation in a Phase 2 celiac disease trial.
A single dose of Teva's experimental antibody significantly reduced gluten-induced intestinal damage and inflammation in a Phase 2 celiac disease trial.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
A single dose of Teva's experimental antibody significantly reduced gluten-induced intestinal damage and inflammation in a Phase 2 celiac disease trial.
Open the app view to save this story, compare related coverage, and continue from the same source.